Susquehanna International Group
ADXN

Susquehanna International Group’s Addex Therapeutics ADXN Stock Holding History

Susquehanna International Group’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-754
Closed -$14.3K – 11950
2023
Q1 		$14.3K Sell
754
-2,853
-79% -$72.1K ﹤0.01% 12136
2022
Q4 		$45.4K Buy
+3,607
New +$53.3K ﹤0.01% 11446

Other funds holding ADXN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Susquehanna International Group's ADXN Position: Q2 2023 in Review

Susquehanna International Group sold out of Addex Therapeutics (ADXN) in Q2 2023, closing a stake of 754 shares — an estimated $14.3K sold.

Susquehanna International Group first reported a position in ADXN in Q4 2022 and held it in 2 quarters. The position peaked at $45.4K in Q4 2022. 3 funds tracked by Wall St. Rank hold ADXN as of Q2 2023.

  • Susquehanna International Group reported no remaining Addex Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Susquehanna International Group sold 754 Addex Therapeutics shares in Q2 2023, an estimated $14.3K.
  • Susquehanna International Group first reported a position in Addex Therapeutics in Q4 2022 and held it in 2 quarters.
  • Susquehanna International Group's Addex Therapeutics position peaked at $45.4K in Q4 2022.
  • 3 funds tracked by Wall St. Rank held Addex Therapeutics as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.